Sunitinib, a targeted therapy medication used in the treatment of advanced kidney cancer (renal cell carcinoma) and gastrointestinal stromal tumors (GIST), has demonstrated efficacy in prolonging overall survival for some patients. Clinical studies have shown that sunitinib treatment can lead to a significant extension of life expectancy compared to placebo or other treatments. However, the exact duration of survival benefit varies among individuals and depends on factors such as cancer stage, overall health, and response to treatment. It's essential for patients to discuss their prognosis and treatment goals with their healthcare provider to gain a better understanding of how sunitinib may impact their life expectancy.